PDCD1 and cancer: Although the clinical success of immune checkpoint inhibitors targeting CTLA4, PD-1, and PD- L1 has revolutionized traditional cancer treatment, response rates have remained limited, indicating that the complexity of co-evolution between cancer cells and the microenvironment may impact the response to immunotherapy.